Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients

Shi, Jichan; He, Guiqing; Ning, Hongye; Wu, Lijun; Wu, Zhengxin; Ye, Xinchun; Qiu, Chaochao; Jiang, Xieyuan

doi:10.1016/j.tube.2022.102209

Cited by 15 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All specimens were processed according to a standardized procedure previously outlined by Conlight TB&DR® Detection (Shanghai Conlight Medical Laboratory Co., Ltd., Shanghai, China) ( Shi et al, 2022 ; Wu et al, 2022 ). The specimens were transported under appropriate cold chain conditions.…”

Section: Methodsmentioning

confidence: 99%

A comparative study of MassARRAY and GeneXpert assay in detecting rifampicin resistance in tuberculosis patients’ clinical specimens

Liang,

Li,

Zhao

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

ObjectivesMatrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has emerged as a potent tool for detecting drug resistance in tuberculosis (TB); however, concerns about its reliability have been raised. In this study, we assessed the reliability of MassARRAY (Sequenom, Inc.), which is a MALDI-TOF MS-based method, by comparing it to the well-established GeneXpert assay (Cepheid) as a reference method.MethodsA retrospective study was conducted using laboratory data retrieved from Henan Chest Hospital (Zhengzhou, China). To ensure a rigorous evaluation, we adopted a comprehensive assessment approach by integrating multiple outcomes of the Xpert assay across various specimen types.ResultsAmong the 170 enrolled TB cases, MassARRAY demonstrated significantly higher sensitivity (85.88%, 146 of 170) compared to the Xpert assay (76.62%, 118 of 154) in TB diagnosis (p < 0.05). The concordance in detecting rifampicin resistance between MassARRAY and the combined outcomes of the Xpert assay was 90%, while it was 97.37% (37 of 38) among smear-positive cases and 89.06% (57 of 64) among culture-positive cases. When compared to the phenotypic susceptibility outcomes of the 12 included drugs, consistency rates of 81.8 to 93.9% were obtained, with 87.9% for multiple drug resistance (MDR) identification.ConclusionMassARRAY demonstrates high reliability in detecting rifampicin resistance, and these findings may offer a reasonable basis for extrapolation to other drugs included in the test panel.

show abstract

Section: Methodsmentioning

confidence: 99%

A comparative study of MassARRAY and GeneXpert assay in detecting rifampicin resistance in tuberculosis patients’ clinical specimens

Liang,

Li,

Zhao

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…DST was conducted for first-line anti-TB drugs including INH, RFP, ethambutol (EMB), and streptomycin (SM), and for second-line drugs including protionamide (PTO), para-aminosalicylic acid (PAS), amikacin (AM), capreomycin (CM), kanamycin (KM), levofloxacin (LFX) and ofloxacin (OFX). The following concentrations of anti-TB drugs were administered according to the proportion method: 0.2 µg/ml for INH, 40.0 µg/ml for RIF, 2.0 µg/ml for EMB, 4.0 µg/ml for SM, 30.0 µg/ml for KM, 2.0 µg/ml for OFX, 2.0 µg/ml for LFX, 40.0 µg/ml for CM, 40.0 µg/ml for AM, 1.0 µg/ml for PAS and 40.0 µg/ml for PTO [21]. Resistance to a specific drug was determined if the growth rate was greater than 1.0% compared to the control [21].…”

Section: Drug Sensitivity Testingmentioning

confidence: 99%

“…The following concentrations of anti-TB drugs were administered according to the proportion method: 0.2 µg/ml for INH, 40.0 µg/ml for RIF, 2.0 µg/ml for EMB, 4.0 µg/ml for SM, 30.0 µg/ml for KM, 2.0 µg/ml for OFX, 2.0 µg/ml for LFX, 40.0 µg/ml for CM, 40.0 µg/ml for AM, 1.0 µg/ml for PAS and 40.0 µg/ml for PTO [21]. Resistance to a specific drug was determined if the growth rate was greater than 1.0% compared to the control [21].…”

Section: Drug Sensitivity Testingmentioning

confidence: 99%

The differences in drug resistance between drug-resistant tuberculosis patients with and without diabetes mellitus in northeast China: a retrospective study

Pan

et al. 2023

BMC Infect Dis

View full text Add to dashboard Cite

Background Diabetes mellitus (DM) and drug-resistant tuberculosis (DR-TB) are serious global public health problems. This study aimed to explore the differences in drug resistance between DR-TB patients with and without DM. Risk factors for developing multidrug-resistant tuberculosis (MDR-TB) were also investigated among DR-TB patients. Methods The patient’s basic demographic,　clinical characteristics, and drug susceptibility testing (DST) data were collected from the Chinese Disease Control Information System. Descriptive statistics were used to estimate the frequency and proportion of included variables. Categorical variables were compared using the Chi-square test or Fisher’s exact test. Chi-square tests for trends were used to determine changes and trends in MDR-TB and pre-extensively drug-resistantTB (pre-XDR-TB) patterns over time. Univariate and multivariate logistic regression analysis was used to explore the risk factors of MDR-TB. Results Compared with DR-TB patients with DM, DR-TB patients without DM had significantly higher rates of mono-resistant streptomycin (SM) and any resistance to kanamycin (KM), but significantly lower rates of any resistance to protionamide (PTO) and mono-resistance to levofloxacin (LFX), and pre-XDR-TB (P<0.05). The proportion of resistance to other anti-TB drugs was not statistically different between the DR-TB with and without DM. Among DR-TB patients without and with DM, the proportion of patients with MDR-TB and pre-XDR-TB patterns showed a significant downward trend from 2016 to 2021 (P<0.05). Among DR-TB patients without DM, male, previously treated DR-TB cases, and immigration were risk factors for MDR-TB (P<0.05). In DR-TB patients with DM, a negative sputum smear is a risk factor for MDR-TB (P<0.05). Conclusion There was no statistical difference in resistance patterns between DR-TB with and without DM, except in arbitrary resistance to PTO and KM, mono-resistant SM and LFX, and pre-XDR-TB. Great progress has been made in the prevention and control of MDR-TB and pre-XDR-TB. However, DR-TB patients with and without DM differ in their risk factors for developing MDR-TB.

show abstract

“…One reaction can amplify up to 40 gene ampli cations that can applied to single nucleotide polymorphism analysis, mutant detection, and other research areas. The speci c procedures can be found in the literatures 11,13 . Brie y, the process includes the following six steps: extraction of nucleic acids from samples, PCR to obtain target fragments, shrimp alkaline phosphatase (SAP) reaction, extension reaction, detection on the MS instrument, and automatic analysis of results by MassARRAY analysis software.…”

Section: Nucleotide Maldi-tof Ms Assaymentioning

confidence: 99%

Evaluation of nucleotide MALDI-TOF MS on bronchoalveolar lavage fluid for pulmonary Tuberculosis: experience from a tertiary hospital in southwestern China

Jiang,

Xin,

Liang

et al. 2024

Preprint

View full text Add to dashboard Cite

To evaluate the diagnostic accuracy of matrix-assisted laser desorption ionization time-of-flight mass spectrometry based on nucleotide (nucleotide MALDI-TOF MS) on bronchoalveolar lavage fluid (BALF) from suspected pulmonary tuberculosis (PTB) patients. A retrospective study was conducted on suspected PTB patients admitted to Chongqing Public Health Medical Center between May 2021 and January 2022. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and area under the curve (AUC) values of nucleotide MALDI-TOF MS as well as smear microscopy, Mycobacterium Growth Indicator Tube 960 culture (MGIT 960 culture), and Xpert MTB/RIF were calculated and compared. Total of 343 presumed PTB cases were enrolled. Overall, using the clinical diagnosis as reference, the sensitivity and NPV of nucleotide MALDI-TOF MSwas 71.5% and 43.1%, respectively, significantly higher than smear microscopy (22.6%, 23.2%), MGIT 960 culture (40.6%, 18.9%), Xpert MTB/RIF (40.8%, 27.9%). Furthermore, nucleotide MALDI-TOF MS also outperformed over Xpert MTB/RIF and MGIT 960 culture on smear-negative BALFs. Approximately 50% and 30% of patients benefited from nucleotide MALDI-TOF MS compared with smear and MGIT 960 culture or Xpert MTB/RIF, respectively. This study demonstrated that the analysis of BALF with nucleotide MALDI-TOF MS provided an accurate and promising tool for the early diagnosis of PTB.

show abstract

Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients

Cited by 15 publications

References 15 publications

A comparative study of MassARRAY and GeneXpert assay in detecting rifampicin resistance in tuberculosis patients’ clinical specimens

A comparative study of MassARRAY and GeneXpert assay in detecting rifampicin resistance in tuberculosis patients’ clinical specimens

The differences in drug resistance between drug-resistant tuberculosis patients with and without diabetes mellitus in northeast China: a retrospective study

Evaluation of nucleotide MALDI-TOF MS on bronchoalveolar lavage fluid for pulmonary Tuberculosis: experience from a tertiary hospital in southwestern China

Contact Info

Product

Resources

About